ArrowMark Partners is an SEC-registered investment adviser.
ArrowMark Partners is an investment management adviser in Colorado that focuses on alternative credit and growth equity asset classes. Founded in 2007 in Denver, Colorado. The firm invests in late stage venture stages and usually invest in Series B, Series C, Series D rounds. The notable investment portfolio of ArrowMark Partners includes Twilio, ORIC Pharmaceuticals, Inhibrx, Pulmonx, and SpringWorks Therapeutics.
As of December 2019, ArrowMark Partners has made 28 investments and had 11 exits. and actively looking for new investment opportunities. The company manages $18.9 billion in assets for traditional and customized investments.